{"id":5527,"date":"2025-02-03T08:57:00","date_gmt":"2025-02-03T07:57:00","guid":{"rendered":"https:\/\/cnatm-1.betapage.de\/?p=5527"},"modified":"2025-02-03T09:09:10","modified_gmt":"2025-02-03T08:09:10","slug":"decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie","status":"publish","type":"post","link":"https:\/\/cnatm.de\/en\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/","title":{"rendered":"Decitabine analogues for the therapy of acute myeloid leukemia"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5527\" class=\"elementor elementor-5527\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6363f8b elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6363f8b\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-807a88d\" data-id=\"807a88d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-0b60e27 elementor-widget elementor-widget-heading\" data-id=\"0b60e27\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Decitabine analogues for the therapy of acute myeloid leukemia<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-39021d3 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"39021d3\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3c861fc\" data-id=\"3c861fc\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-553a889 elementor-widget elementor-widget-spacer\" data-id=\"553a889\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39a4d74 elementor-widget elementor-widget-text-editor\" data-id=\"39a4d74\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Decitabine is a synthetic nucleoside that can significantly slow the progression of acute myeloid leukaemia (AML) through an epigenetic mechanism that is not fully understood. However, this is not seen in all patients and toxic side effects are common. Preliminary work in WP1 has shown that decitabine can be chemically modified to increase its stability and reduce unwanted side effects. The aim of this WP is to develop decitabine analogs with even better pharmacological properties.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-72d739a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"72d739a\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-89f255c\" data-id=\"89f255c\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-89a1439 elementor-widget elementor-widget-text-editor\" data-id=\"89a1439\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Head: Thomas Carell<\/strong><\/p><p><strong>PIs:<\/strong> Thomas Carell, Pascal Giehr, Irmel Jeremias, Pavel Kielkowski, Franziska Traube<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-4e4729f\" data-id=\"4e4729f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4022c7e elementor-widget elementor-widget-text-editor\" data-id=\"4022c7e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>\u00a0Industrial partner<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ecb4f9e elementor-widget elementor-widget-image\" data-id=\"ecb4f9e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"307\" src=\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH-1024x307.png\" class=\"attachment-large size-large wp-image-4772\" alt=\"Eisbach Bio GmbH\" srcset=\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH-1024x307.png 1024w, https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH-300x90.png 300w, https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH-768x230.png 768w, https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH-1536x461.png 1536w, https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH-18x5.png 18w, https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png 2000w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie Decitabin ist ein synthetisches Nukleosid, das das Fortschreiten der akuten myeloischen Leuk\u00e4mie (AML) durch einen epigenetischen Mechanismus, der noch nicht vollst\u00e4ndig verstanden ist, erheblich verlangsamen kann. Dies ist jedoch nicht bei allen Patienten der Fall, und es treten h\u00e4ufig toxische Nebenwirkungen auf. Vorarbeiten im WP1 haben [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":5528,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[73],"tags":[],"class_list":["post-5527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mono-und-dinukleotide"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie - CNATM<\/title>\n<meta name=\"description\" content=\"Decitabin ist ein synthetisches Nukleosid, das das Fortschreiten der akuten myeloischen Leuk\u00e4mie (AML) durch einen epigenetischen Mechanismus, der noch nicht vollst\u00e4ndig verstanden ist, erheblich verlangsamen kann.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cnatm.de\/en\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie - CNATM\" \/>\n<meta property=\"og:description\" content=\"Decitabin ist ein synthetisches Nukleosid, das das Fortschreiten der akuten myeloischen Leuk\u00e4mie (AML) durch einen epigenetischen Mechanismus, der noch nicht vollst\u00e4ndig verstanden ist, erheblich verlangsamen kann.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cnatm.de\/en\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/\" \/>\n<meta property=\"og:site_name\" content=\"CNATM\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-03T07:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T08:09:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cnatm.de\/wp-content\/uploads\/2025\/02\/WP1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"916\" \/>\n\t<meta property=\"og:image:height\" content=\"655\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Patrizia Torelli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patrizia Torelli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/\"},\"author\":{\"name\":\"Patrizia Torelli\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/person\\\/f2fc8eccad93916c1b891b5fef1ac19e\"},\"headline\":\"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie\",\"datePublished\":\"2025-02-03T07:57:00+00:00\",\"dateModified\":\"2025-02-03T08:09:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/\"},\"wordCount\":120,\"publisher\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/WP1.png\",\"articleSection\":[\"Mono- und Dinukleotide\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/\",\"url\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/\",\"name\":\"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie - CNATM\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/WP1.png\",\"datePublished\":\"2025-02-03T07:57:00+00:00\",\"dateModified\":\"2025-02-03T08:09:10+00:00\",\"description\":\"Decitabin ist ein synthetisches Nukleosid, das das Fortschreiten der akuten myeloischen Leuk\u00e4mie (AML) durch einen epigenetischen Mechanismus, der noch nicht vollst\u00e4ndig verstanden ist, erheblich verlangsamen kann.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/WP1.png\",\"contentUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/WP1.png\",\"width\":916,\"height\":655,\"caption\":\"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#website\",\"url\":\"https:\\\/\\\/cnatm.de\\\/\",\"name\":\"CNATM\",\"description\":\"Cluster for Nucleic Acid Therapeutics Munich\",\"publisher\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cnatm.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#organization\",\"name\":\"CNATM\",\"url\":\"https:\\\/\\\/cnatm.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"contentUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"width\":2362,\"height\":479,\"caption\":\"CNATM\"},\"image\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/person\\\/f2fc8eccad93916c1b891b5fef1ac19e\",\"name\":\"Patrizia Torelli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"caption\":\"Patrizia Torelli\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie - CNATM","description":"Decitabin ist ein synthetisches Nukleosid, das das Fortschreiten der akuten myeloischen Leuk\u00e4mie (AML) durch einen epigenetischen Mechanismus, der noch nicht vollst\u00e4ndig verstanden ist, erheblich verlangsamen kann.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cnatm.de\/en\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/","og_locale":"en_US","og_type":"article","og_title":"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie - CNATM","og_description":"Decitabin ist ein synthetisches Nukleosid, das das Fortschreiten der akuten myeloischen Leuk\u00e4mie (AML) durch einen epigenetischen Mechanismus, der noch nicht vollst\u00e4ndig verstanden ist, erheblich verlangsamen kann.","og_url":"https:\/\/cnatm.de\/en\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/","og_site_name":"CNATM","article_published_time":"2025-02-03T07:57:00+00:00","article_modified_time":"2025-02-03T08:09:10+00:00","og_image":[{"width":916,"height":655,"url":"https:\/\/cnatm.de\/wp-content\/uploads\/2025\/02\/WP1.png","type":"image\/png"}],"author":"Patrizia Torelli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Patrizia Torelli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/#article","isPartOf":{"@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/"},"author":{"name":"Patrizia Torelli","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e"},"headline":"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie","datePublished":"2025-02-03T07:57:00+00:00","dateModified":"2025-02-03T08:09:10+00:00","mainEntityOfPage":{"@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/"},"wordCount":120,"publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"image":{"@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2025\/02\/WP1.png","articleSection":["Mono- und Dinukleotide"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/","url":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/","name":"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie - CNATM","isPartOf":{"@id":"https:\/\/cnatm.de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/#primaryimage"},"image":{"@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2025\/02\/WP1.png","datePublished":"2025-02-03T07:57:00+00:00","dateModified":"2025-02-03T08:09:10+00:00","description":"Decitabin ist ein synthetisches Nukleosid, das das Fortschreiten der akuten myeloischen Leuk\u00e4mie (AML) durch einen epigenetischen Mechanismus, der noch nicht vollst\u00e4ndig verstanden ist, erheblich verlangsamen kann.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/decitabin-analoga-fuer-die-therapie-der-akuten-myeloischen-leukaemie\/#primaryimage","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2025\/02\/WP1.png","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2025\/02\/WP1.png","width":916,"height":655,"caption":"Decitabin Analoga f\u00fcr die Therapie der akuten myeloischen Leuk\u00e4mie"},{"@type":"WebSite","@id":"https:\/\/cnatm.de\/#website","url":"https:\/\/cnatm.de\/","name":"CNATM","description":"Cluster for Nucleic Acid Therapeutics Munich","publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cnatm.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cnatm.de\/#organization","name":"CNATM","url":"https:\/\/cnatm.de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","width":2362,"height":479,"caption":"CNATM"},"image":{"@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e","name":"Patrizia Torelli","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","caption":"Patrizia Torelli"}}]}},"_links":{"self":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/5527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/comments?post=5527"}],"version-history":[{"count":6,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/5527\/revisions"}],"predecessor-version":[{"id":5546,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/5527\/revisions\/5546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media\/5528"}],"wp:attachment":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media?parent=5527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/categories?post=5527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/tags?post=5527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}